Compounds > bromofosfamide
Page last updated: 2024-11-07

bromofosfamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bromofosfamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128500
CHEMBL ID78097
SCHEMBL ID10783111
MeSH IDM0199421

Synonyms (23)

Synonym
CHEMBL78097
2h-1,3,2-oxazaphosphorin-2-amine, n-(2-bromoethyl)-3-(2-chloroethyl)tetrahydro-, 2-oxide
km 135
2h-1,3,2-oxazaphosphorin-2-amine, n-(2-bromoethyl)-3-(2-chloroethyl)tetrahydro-, 2-oxide, (+-)-
2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-, 2-oxide, (+-)-
brn 6768452
tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide
bromofosfamide
2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-, 2-oxide
146452-36-0
104149-14-6
unii-j92cv4atfn
j92cv4atfn ,
SCHEMBL10783111
2-[(2-bromoethyl)amino]-3-(2-chloroethyl)-1,3,2lambda5-oxazaphosphinan-2-one
AKOS033887619
Z1269230176
n-(2-bromoethyl)-3-(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
2-((2-bromoethyl)amino)-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide
Q27281361
2-[(2-bromoethyl)amino]-3-(2-chloroethyl)-1,3,2lambda~5~-oxazaphosphinan-2-one
DTXSID70908827
EN300-260081

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats."( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, )		0.38
" Its pharmacokinetics and bioavailability were studied in female mice following intravenous and oral administration of the dose of 50 mg/kg."( Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice.
Kobylińska, K; Kobylińska, M; Sobik, B, 2001)		0.6

Dosage Studied

ExcerptRelevanceReference
"Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats."( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, )		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID135975Number of mice that survived on day 60 at a dose of 80 mg/kg; 7/251988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135974Number of mice that survived on day 60 at a dose of 60 mg/kg; 4/601988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130311Percentage increase in life span of L1210 leukemia implanted mice at a dose of 200 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135956Number of mice that survived on day 60 at a dose of 200 mg/kg; 23/271988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135971Number of mice that survived on day 60 at a dose of 50 mg/kg; 0/71988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135940Number of mice that survived on day 60 at a dose of 100 mg/kg; 24/461988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135960Number of mice that survived on day 60 at a dose of 300 mg/kg; 14/191988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135947Number of mice that survived on day 60 at a dose of 150 mg/kg; 16/231988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID135968Number of mice that survived on day 60 at a dose of 400 mg/kg; 8/121988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130315Percentage increase in life span of L1210 leukemia implanted mice at a dose of 400 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130306Percentage increase in life span of L1210 leukemia implanted mice at a dose of 120 50 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130309Percentage increase in life span of L1210 leukemia implanted mice at a dose of 150 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID134723Lethal dose to kill 50% of the mice after single ip injection to healthy female CD2F1 mice1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130305Percentage increase in life span of L1210 leukemia implanted mice at a dose of 100 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID132249Effective dose that causes 50% increase in life span of mice1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130319Percentage increase in life span of L1210 leukemia implanted mice at a dose of 60 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130320Percentage increase in life span of L1210 leukemia implanted mice at a dose of 80 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
AID130314Percentage increase in life span of L1210 leukemia implanted mice at a dose of 300 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's2 (25.00)18.2507
2000's5 (62.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ifosfamide
[no description available]		5.9881ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
isophosphamide mustard
isophosphamide mustard: antitumor metabolite of ifosfamide; palifosfamide-tris is a salt with tris; structure in first source		1.9810phosphorodiamide
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.3920
Adenocarcinoma, Basal Cell
[description not available]		0210
Cancer of Colon
[description not available]		0210
Plasma Cell Tumor
[description not available]		0210
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		0210
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		0210
B16 Melanoma
[description not available]		0210
Bone Marrow Diseases
Diseases involving the BONE MARROW.		03.3911
Carcinoma, Non-Small Cell Lung
[description not available]		03.3911
Cancer of Lung
[description not available]		03.3911
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.3911
Lung Neoplasms
Tumors or cancer of the LUNG.		03.3911